Bioinformatics Analysis of Choriocarcinoma-Related MicroRNA-Transcription Factor-Target Gene Regulatory Networks and Validation of Key miRNAs

References

• Cheung A, Zhang H, Xue W, Siu M. Pathogenesis of choriocarcinoma: clinical, genetic and stem cell perspectives. Future Oncol. 2009;5(2):217–231. doi:10.2217/14796694.5.2.217
   PubMed Web of Science ®Google Scholar
• Jung S, Choi Y, Kim M, et al. Distinct genomic profiles of gestational choriocarcinoma, a unique cancer of pregnant tissues. Exp Mol Med. 2020;52(12):2046–2054. doi:10.1038/s12276-020-00544-0
   PubMed Web of Science ®Google Scholar
• Lok C, Frijstein M, van Trommel N. Clinical presentation and diagnosis of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol. 2020. doi:10.1016/j.bpobgyn.2020.12.001
   PubMed Web of Science ®Google Scholar
• Gulyaeva L, Kushlinskiy N. Regulatory mechanisms of microRNA expression. J Transl Med. 2016;14(1):143. doi:10.1186/s12967-016-0893-x
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack F. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222. doi:10.1038/nrd.2016.246
   PubMed Web of Science ®Google Scholar
• Chaiwangyen W, Ospina-Prieto S, Photini S, Schleussner E, Markert U, Morales-Prieto D. Dissimilar microRNA-21 functions and targets in trophoblastic cell lines of different origin. Int J Biochem Cell Biol. 2015;68:187–196. doi:10.1016/j.biocel.2015.08.018
   PubMed Web of Science ®Google Scholar
• Lin LH, Maestá I, St Laurent JD, et al. Braga at risk of malignant progression. Am J Obstet Gynecol. 2021;224(4):372.e1–372.e30. doi:10.1016/j.ajog.2020.09.048
   Web of Science ®Google Scholar
• Pang R, Leung C, Lee C, et al. MicroRNA-34a is a tumor suppressor in choriocarcinoma via regulation of delta-like1. BMC Cancer. 2013;13:25. doi:10.1186/1471-2407-13-25
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao J, Xu Y, Wu W, Zhang H. miR-21 is overexpressed in hydatidiform mole tissues and promotes proliferation, migration, and invasion in choriocarcinoma cells. Int J Gynecol Cancer. 2017;27(2):364–374. doi:10.1097/IGC.0000000000000861
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang S, Zhang Y, Qian J. Identification of MicroRNA-target gene-transcription factor regulatory networks in colorectal adenoma using microarray expression data. Front Genet. 2020;11:463. doi:10.3389/fgene.2020.00463
   PubMed Web of Science ®Google Scholar
• Bilban M, Tauber S, Haslinger P, et al. Trophoblast invasion: assessment of cellular models using gene expression signatures. Placenta. 2010;31(11):989–996. doi:10.1016/j.placenta.2010.08.011
   PubMed Web of Science ®Google Scholar
• Morales-Prieto D, Chaiwangyen W, Ospina-Prieto S, et al. MicroRNA expression profiles of trophoblastic cells. Placenta. 2012;33(9):725–734. doi:10.1016/j.placenta.2012.05.009
   PubMed Web of Science ®Google Scholar
• Morales-Prieto D, Barth E, Murrieta-Coxca J, et al. Identification of miRNAs and associated pathways regulated by leukemia inhibitory factor in trophoblastic cell lines. Placenta. 2019;88:20–27. doi:10.1016/j.placenta.2019.09.005
   PubMed Web of Science ®Google Scholar
• Chen H, Boutros P. VennDiagram: a package for the generation of highly-customizable venn and euler diagrams in R. BMC Bioinform. 2011;12(1):35. doi:10.1186/1471-2105-12-35
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091–1093. doi:10.1093/bioinformatics/btp101
   PubMed Web of Science ®Google Scholar
• Bader G, Hogue C. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003;4(1):2. doi:10.1186/1471-2105-4-2
   PubMed Web of Science ®Google Scholar
• Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods. 2015;12(8):697. doi:10.1038/nmeth.3485
   PubMed Web of Science ®Google Scholar
• Krek A, Grün D, Poy M, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495–500. doi:10.1038/ng1536
   PubMed Web of Science ®Google Scholar
• Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet. 2007;39(10):1278–1284. doi:10.1038/ng2135
   PubMed Web of Science ®Google Scholar
• Miranda K, Huynh T, Tay Y, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell. 2006;126(6):1203–1217. doi:10.1016/j.cell.2006.07.031
   PubMed Web of Science ®Google Scholar
• Krüger J, Rehmsmeier M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res. 2006;34:W451–W454. doi:10.1093/nar/gkl243
   PubMed Web of Science ®Google Scholar
• Lewis B, Burge C, Bartel D. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20. doi:10.1016/j.cell.2004.12.035
   PubMed Web of Science ®Google Scholar
• Janky R, Verfaillie A, Imrichová H, et al. iRegulon: from a gene list to a gene regulatory network using large motif and track collections. PLoS Comput Biol. 2014;10(7):e1003731. doi:10.1371/journal.pcbi.1003731
   PubMed Web of Science ®Google Scholar
• Shi YF, Li JQ, Zheng W, et al. Survey of gestational trophoblastic disease incidence among 3.6 million pregnancies in China. China J Obstet Gynecol. 2005;40(2):76–78.
   Google Scholar
• Steigrad SJ. Epidemiology of gestational trophoblastic disease. Best Res Clin Obstet Gynaecol. 2003;17(6):837–847. doi:10.1016/S1521-6934(03)00049-X
   PubMed Web of Science ®Google Scholar
• Freitas F, Braga A, Viggiano M, et al. Gestational trophoblastic neoplasia lethality among Brazilian women: a retrospective national cohort study. Gynecol Oncol. 2020;158:452–459. doi:10.1016/j.ygyno.2020.04.704
   PubMed Web of Science ®Google Scholar
• Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci. 2016;17(10):1712. doi:10.3390/ijms17101712
   PubMed Web of Science ®Google Scholar
• Wang L, Wang W, Xu Y, Wang Q. Low Levels of SPARC are associated with tumor progression and poor prognosis in human endometrial carcinoma. Onco Targets Ther. 2020;13:11549–11569. doi:10.2147/OTT.S277795
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhu Y, Shi Y, et al. Downregulation of SPARC expression inhibits the invasion of human trophoblast cells in vitro. PLoS One. 2013;8(7):e69079. doi:10.1371/journal.pone.0069079
   PubMed Web of Science ®Google Scholar
• Chen Y, Qian H, Zhang Y, Ma Y, Lin C, Xiang Y. Effect of Ad-TIMP3 on biologic behavior of choriocarcinoma cells in vitro. J Reprod Med. 2008;53(8):608–614.
   PubMed Web of Science ®Google Scholar
• Godbole G, Suman P, Gupta S, Modi D. Decidualized endometrial stromal cell derived factors promote trophoblast invasion. Fertil Steril. 2011;95(4):1278–1283. doi:10.1016/j.fertnstert.2010.09.045
   PubMed Web of Science ®Google Scholar
• Mascaró M, Pibuel M, Lompardía S, et al. Low molecular weight hyaluronan induces migration of human choriocarcinoma JEG-3 cells mediated by RHAMM as well as by PI3K and MAPK pathways. Histochem Cell Biol. 2017;148(2):173–187. doi:10.1007/s00418-017-1559-3
   PubMed Web of Science ®Google Scholar
• Lan X, Fu L, Hu Z, et al. Methylated oligonucleotide (MON)-induced promoter hypermethylation is associated with repression of CDH1 expression and contributes to the migration and invasion of human trophoblast cell lines. Reprod Fertil Dev. 2017;29(8):1509–1520. doi:10.1071/RD16031
   PubMed Web of Science ®Google Scholar
• Xu G, Chakraborty C, Lala P. Expression of TGF-beta signaling genes in the normal, premalignant, and malignant human trophoblast: loss of smad3 in choriocarcinoma cells. Biochem Biophys Res Commun. 2001;287(1):47–55. doi:10.1006/bbrc.2001.5533
   PubMed Web of Science ®Google Scholar
• Liu Z, Liu H, Fang W, Yang Y, Wang H, Peng J. Insulin-like growth factor binding protein 7 modulates estrogen-induced trophoblast proliferation and invasion in HTR-8 and JEG-3 cells. Cell Biochem Biophys. 2012;63(1):73–84. doi:10.1007/s12013-012-9342-5
   PubMed Web of Science ®Google Scholar
• Feng H, Cheung A, Xue W, et al. Down-regulation and promoter methylation of tissue inhibitor of metalloproteinase 3 in choriocarcinoma. Gynecol Oncol. 2004;94(2):375–382. doi:10.1016/j.ygyno.2004.04.019
   PubMed Web of Science ®Google Scholar
• Adiga D, Eswaran S, Pandey D, Sharan K, Kabekkodu S. Molecular landscape of recurrent cervical cancer. Crit Rev Oncol Hematol. 2021;157:103178.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7(3):339–348. doi:10.15171/apb.2017.041
   PubMed Web of Science ®Google Scholar
• Liu S, Kasherman L, Fazelzad R, et al. The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2021;161(2):601–612. doi:10.1016/j.ygyno.2021.01.028
   PubMed Web of Science ®Google Scholar
• Gaibar M, Galán M, Romero-Lorca A, et al. ANGPT1Genetic variants of, and linked to clinical outcome of bevacizumab plus chemotherapy for metastatic colorectal cancer. Int J Mol Sci. 2021;22:3. doi:10.3390/ijms22031381
   Web of Science ®Google Scholar
• Tamiya M, Tamiya A, Suzuki H, et al. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion. Invest New Drugs. 2021. doi:10.1007/s10637-021-01076-8
   Web of Science ®Google Scholar
• Vaishampayan U, Heilbrun L, Monk P, et al. Clinical efficacy of enzalutamide vs bicalutamide combined with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a randomized clinical trial. JAMA Netw Open. 2021;4(1):e2034633. doi:10.1001/jamanetworkopen.2020.34633
   PubMed Web of Science ®Google Scholar
• Christodoulou C, Kalogera-Fountzila A, Karavasilis V, et al. Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a Phase II study of the Hellenic Cooperative Oncology Group (HeCOG). J Neurooncol. 2017;134(2):443–451. doi:10.1007/s11060-017-2548-z
   PubMed Web of Science ®Google Scholar
• Khan M, Zhao Z, Arooj S, et al. Lapatinib plus local radiation therapy for brain metastases from HER-2 positive breast cancer patients and role of trastuzumab: a systematic review and meta-analysis. Front Oncol. 2020;10:576926. doi:10.3389/fonc.2020.576926
   PubMed Web of Science ®Google Scholar
• Cooper O, Bonert V, Rudnick J, et al. EGFR/ErbB2-targeting lapatinib therapy for aggressive prolactinomas. J Clin Endocrinol Metab. 2020;13(2):e917–e925. doi:10.1210/clinem/dgaa805
   Google Scholar
• Shepard G, Arrowsmith E, Murphy P, et al. A Phase II Study with lead-in safety cohort of 5-fluorouracil, oxaliplatin, and lapatinib in combination with radiation therapy as neoadjuvant treatment for patients with localized HER2-positive esophagogastric adenocarcinomas. Oncologist. 2017;22(10):1152–e1198. doi:10.1634/theoncologist.2017-0186
   PubMed Web of Science ®Google Scholar
• Zhou W, She G, Yang K, Zhang B, Liu J, Yu B. MiR-384 inhibits proliferation and migration of trophoblast cells via targeting PTBP3. Pregnancy Hypertens. 2020;21:132–138. doi:10.1016/j.preghy.2020.05.017
   PubMed Web of Science ®Google Scholar
• Wang C, Bian Z, Wei D, Zhang J. miR-29b regulates migration of human breast cancer cells. Mol Cell Biochem. 2011;352:197–207. doi:10.1007/s11010-011-0755-z
   PubMed Web of Science ®Google Scholar
• Wang C, Gao C, Zhuang J, Ding C, Wang Y. A combined approach identifies three mRNAs that are down-regulated by microRNA-29b and promote invasion ability in the breast cancer cell line MCF-7. J Cancer Res Clin Oncol. 2012;138(12):2127–2136. doi:10.1007/s00432-012-1288-x
   PubMed Web of Science ®Google Scholar
• Sugio A, Iwasaki M, Habata S, et al. BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer. Gynecol Oncol. 2014;134(3):615–623. doi:10.1016/j.ygyno.2014.06.024
   PubMed Web of Science ®Google Scholar
• Okamoto K, Miyoshi K, Murawaki Y, Sarkar D. miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS One. 2013;8(10):e77623. doi:10.1371/journal.pone.0077623
   PubMed Web of Science ®Google Scholar
• Lv L, Deng H, Li Y, et al. The DNA methylation-regulated miR-193a-3p dictates the multi-chemoresistance of bladder cancer via repression of SRSF2/PLAU/HIC2 expression. Cell Death Dis. 2014;5(9):e1402. doi:10.1038/cddis.2014.367
   PubMedGoogle Scholar
• Ma Y, Zhu J, Chen S, et al. Low expression of SPARC in gastric cancer-associated fibroblasts leads to stemness transformation and 5-fluorouracil resistance in gastric cancer. Cancer Cell Int. 2019;19(1):137. doi:10.1186/s12935-019-0844-8
   PubMedGoogle Scholar
• Ma X, Wei J, Zhang L, et al. miR-486-5p inhibits cell growth of papillary thyroid carcinoma by targeting fibrillin-1. Biomed Pharmacother. 2016;80:220–226. doi:10.1016/j.biopha.2016.03.020
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu Y, Lu L, et al. Fibrillin-1, induced by aurora-A but inhibited by BRCA2, promotes ovarian cancer metastasis. Oncotarget. 2015;6(9):6670–6683. doi:10.18632/oncotarget.3118
   PubMedGoogle Scholar
• Che X, Jian F, Wang Y, et al. FBXO2 promotes proliferation of endometrial cancer by ubiquitin-mediated degradation of FBN1 in the regulation of the cell cycle and the autophagy pathway. Front Cell Dev Biol. 2020;8:843. doi:10.3389/fcell.2020.00843
   PubMed Web of Science ®Google Scholar
• Abdelmohsen K, Kim M, Srikantan S, et al. miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle. 2010;9(7):1354–1359. doi:10.4161/cc.9.7.11164
   PubMed Web of Science ®Google Scholar
• Cha S, Chen P, Johansson G, et al. MicroRNA-519c suppresses hypoxia-inducible factor-1α expression and tumor angiogenesis. Cancer Res. 2010;70(7):2675–2685. doi:10.1158/0008-5472.CAN-09-2448
   PubMed Web of Science ®Google Scholar
• Tian Z, Yang G, Jiang P, Zhang L, Wang J, Sun S. Long non-coding RNA Sox4 promotes proliferation and migration by activating Wnt/β-catenin signaling pathway in osteosarcoma. Pharmazie. 2017;72(9):537–542. doi:10.1691/ph.2017.7548
   PubMed Web of Science ®Google Scholar
• Jafarnejad S, Ardekani G, Ghaffari M, Li G. Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis. Cell Mol Life Sci. 2013;70(15):2677–2696.
   PubMed Web of Science ®Google Scholar
• Zhang R, Li L, Chen L, et al. MAP7 interacts with RC3H1 and cooperatively regulate cell-cycle progression of cervical cancer cells via activating the NF-κB signaling. Biochem Biophys Res Commun. 2020;527(1):56–63. doi:10.1016/j.bbrc.2020.04.008
   PubMed Web of Science ®Google Scholar
• Xu X, Tao R, Sun L, Ji X. Exosome-transferred hsa_circ_0014235 promotes DDP chemoresistance and deteriorates the development of non-small cell lung cancer by mediating the miR-520a-5p/CDK4 pathway. Cancer Cell Int. 2020;20(1):552. doi:10.1186/s12935-020-01642-9
   PubMed Web of Science ®Google Scholar
• Van der Auwera I, Limame R, van Dam P, Vermeulen P, Dirix L, Van Laere S. Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer. 2010;103(4):532–541. doi:10.1038/sj.bjc.6605787
   PubMed Web of Science ®Google Scholar
• Hromadnikova I, Kotlabova K, Krofta L, Hron F. Follow-up of gestational trophoblastic disease/neoplasia via quantification of circulating nucleic acids of placental origin using C19MC microRNAs, hypermethylated RASSF1A, and SRY sequences. Tumour Biol. 2017;39(4):1010428317697548. doi:10.1177/1010428317697548
   Google Scholar
• Dewerchin M, Carmeliet P. Placental growth factor in cancer. Expert Opin Ther Targets. 2014;18(11):1339–1354. doi:10.1517/14728222.2014.948420
   PubMed Web of Science ®Google Scholar
• Tilborghs S, Corthouts J, Verhoeven Y, et al. The role of nuclear factor-kappa B signaling in human cervical cancer. Crit Rev Oncol Hematol. 2017;120:141–150. doi:10.1016/j.critrevonc.2017.11.001
   PubMed Web of Science ®Google Scholar
• Yin P, Wang W, Zhang Z, Bai Y, Gao J, Zhao C. Wnt signaling in human and mouse breast cancer: focusing on Wnt ligands, receptors and antagonists. Cancer Sci. 2018;109(11):3368–3375. doi:10.1111/cas.13771
   PubMed Web of Science ®Google Scholar
• Tsakiridis I, Giouleka S, Kalogiannidis I, Mamopoulos A, Athanasiadis A, Dagklis T. Diagnosis and management of gestational trophoblastic disease: a comparative review of National and International Guidelines. Obstet Gynecol Surv. 2020;75(12):747–756. doi:10.1097/OGX.0000000000000848
   PubMed Web of Science ®Google Scholar